The inspection in October 2019 identified further chronic non-compliance with EU GMP and failure to adequately address deficiencies from previous inspections. In process checks were not performed effectively and an adequate risk based approach to cross contamination control was not demonstrated. Action taken/proposed by the NCA: Withdrawal, of current valid GMP certificate No. UK GMP 31201 Insp GMP 31201/349094-0008 Withdrawal of previous GMP Certificate No: UK GMP 31201 Insp GMP 31201/349094-0008 Issue of a statement of non-compliance. Prohibition of supply Only batches of critical products to be supplied to EU markets while this statement of non-compliance remains in force.
Inspection Record
MEDOPHARM PRIVATE LIMITED — EU GMP NCR (EudraGMDP) Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
1Contamination control
About this record
Extracted automatically from the document EMA (Europe) published on 2020-02-13. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
